InterCure Ltd.(INCR)Earnings, Financials & Key Ratios
INCR•NASDAQ
$1.04
Price updated Jun 27, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.Show more
- Revenue$239M-32.8%
- EBITDA-$52M-82.5%
- Net Income-$68M-9.4%
- EPS (Diluted)-1.42-4.4%
- Gross Margin12.66%-57.2%
- EBITDA Margin-21.7%-171.7%
- Operating Margin-28.14%-140.7%
- Net Margin-28.38%-62.9%
- ROE-15.86%-25.3%
INCR Price & Volume
InterCure Ltd. (INCR) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Margin Stability
Investment Thesis • Updated 2025Q2
VerdictNegative
Growth:Contracting
Profitability:Strained
Financial Position:Healthy
Cash Flow:Mixed
Primary Risk:Geopolitical and Regulatory Volatility
"InterCure faces a challenging transition as its vertically integrated medical cannabis model struggles with significant revenue contraction, falling from $106.2 million in 2023Q1 to $65.0 million by 2025Q2. While the company maintains a conservative debt-to-equity ratio of 0.41, the reliance on $224.8 million in goodwill and erratic operating margins suggests that the current retail-heavy strategy lacks the necessary scale for consistent profitability. Investors should monitor the company's ability to manage working capital, which recently caused a $7.5 million cash outflow, against the backdrop of ongoing geopolitical and regulatory volatility."
Verdict Logic
the company's inability to maintain consistent profitability, highlighted by a net loss of $852.0K in 2025Q2 and a significant revenue decline, suggests that the current business model remains structurally fragile.
INCR Growth Metrics
InterCure Ltd. (INCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years45.41%
5 Years92.97%
3 Years2.83%
TTM-10.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9.52%
Return on Capital
10 Years-12.26%
5 Years-3.38%
3 Years-3.42%
Last Year-12.26%
Peers Comparison
Key metrics vs top competitors for InterCure Ltd. (INCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.04 | $56.87M | -2.20 | -32.82% | -28.38% | -15.86% | — | |
| $2.81 | $1.05B | -114.69 | 64.4% | -0.98% | -0.18% | — | |
| $4.64 | $540.66M | -0.14 | 4.84% | -252.55% | -136.55% | — | |
| $0.95 | $364.16M | -1.52 | 5.8% | -91.63% | -38.64% | — | |
| $2.83 | $175.3M | -1.87 | -6.37% | -24.14% | -13.4% | — | |
| $69.91 | $4.07B | 28.30 | -3.93% | 3.27% | — | — |
Compare INCR vs Peers
InterCure Ltd. (INCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when INCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INCR Frequently Asked Questions
InterCure Ltd. (INCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is InterCure Ltd.'s revenue?
InterCure Ltd. (INCR) reported $243.1M in revenue for fiscal year 2024. This represents a 1914% increase from $12.1M in 2011.
How fast is InterCure Ltd. growing?
InterCure Ltd. (INCR) saw revenue decline by 32.8% over the past year.
Is INCR profitable?
InterCure Ltd. (INCR) reported a net loss of $70.9M for fiscal year 2024.
Dividend & Returns
What is INCR's return on equity?
InterCure Ltd. (INCR) has a return on equity (ROE) of -15.9%. Negative ROE indicates the company is unprofitable.
What is InterCure Ltd.'s free cash flow?
InterCure Ltd. (INCR) generated $9.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.